ALK and non-small cell lung carcinoma: In this randomized phase 2 clinical trial, patients with resectable stage IIIA or IIIB (T3N2) NSCLC (EGFR and ALK mutation/alteration included) were treated with three cycles of camrelizumab (an anti-PD1 ICI) plus chemotherapy or chemotherapy alone followed by surgery.